Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues

Minerva Endocrinologica

Volumn 38, Issue 3, 2013, Pages 321-328

  Pitocco, D ^a   Rizzi, A ^a   Scavone, G ^a   Tanese, L ^a   Zaccardi, F ^a   Manto, A ^a   Ghirlanda, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Diabetes mellitus; Insulin; Receptor, insulin

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; SHORT ACTING INSULIN;

CATHETER OCCLUSION; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG EFFICACY; DRUG SAFETY; FETUS DEATH; FETUS MALFORMATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN RELEASE; KETOACIDOSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; QUALITY OF LIFE; REVIEW;

ADOLESCENT; ADULT; CHILD; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; FEMALE; HUMANS; HYPOGLYCEMIA; INFUSIONS, SUBCUTANEOUS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN ASPART; INSULIN INFUSION SYSTEMS; INSULIN LISPRO; INSULIN, SHORT-ACTING; MULTICENTER STUDIES AS TOPIC; PREGNANCY; PREGNANCY IN DIABETICS;

EID: 84890183141     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. Diabetologia 2006;49:660-6. (Pubitemid 43357538)
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
3. Triantafillos D. Fotios iliadis insulin pump therapy in adults. Diabetes Res Clin Practice 2005;93S:S109-S13.
4. Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM; Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care 2008;31:210-5. (Pubitemid 351213321)
5. Vasiliki V. Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps. Exp Diabetes Res 2010;2010:178372.
6. Pickup J. Insulin pumps. Diabetes Technology and Therapeutics 2013;15(Suppl. 1).
7. Fendler W, Baranowska AI, Mianowska B, Szadkowska A, Mlynarski W. Three-year comparison of subcutaneous insulin pump treatment with multi-daily injections on HbA1c, its variability and hospital burden of children with type 1 diabetes. Acta Diabetol 2012;49:363-70.
8. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetioc patients previously treated with CSII. Diabetes Care 2005;28:533-8. (Pubitemid 40315309)
9. Bruttomesso D, Bonomo M, Costa S, Dal Pos M, Di Cianni G, Pellicano F et al. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin-glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI). Diabetes Metab 2011;37:426-31.
10. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes. A randomized, parallel-group, 24-week study. Diabetes Care 2003;26:2598-603. (Pubitemid 37052106)
11. Parkner T, Laursen T, Vestergaard ET, Hartvig H, Smedegaard JS, Lauritzen T et al. Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-actiong insulin in type 2 diabetes. Diabetic Medicine 2008;25:585-91. (Pubitemid 351590882)
12. Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003;20:863-6. (Pubitemid 41701510)
13. Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. A randomized study in type 1 diabetes. Diabetes Care 2002;25:439-44. (Pubitemid 41103333)
14. Bode BW. Comparison of pharmakokinetic propreties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues- aspart, lispro, and glulisine. Endocr Pract 2011;17(No.2).
15. Wittlin SD, Marcus AO, Weng CS, Howard CP, Schorr AB; CONTROL Study Group. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion. Diabetes Technol Ther 2008;10:1-10.
16. Bartolo PD, Pellicano F, Scaramuzza A, Sardu C, Casetti T, Bosi E et al. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol Ther 2008;10:495-8.
17. Hoogma RPL, Schumicki D. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res 2006;38:429-33. (Pubitemid 44047966)
18. Senstius J, Poulsen C, Hvass A. Comparison in vitro stability for insulin aspart and insulin glulisine during simulated use in infusion pumps. Diabetes Technol Ther 2007;9:517-21. (Pubitemid 350158794)
19. van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administeres by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther 2011;13:607-14.
20. Jovanovic L. Letter written in response to van Bon et al. insulin glulisine compared to insulin aspart and to insulin lispro administeres by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther 2001;13.
21. Kerr D, Morton J, Whately-Smith C, Everett J, Begley JP. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Technol 2008;2:450-5
22. Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes Metab Res Rev 2009;25.99-111.
23. Lukàcs A Benefits of continuous subcutaneous insulin infusion on quality of life. Int J Technol Assess Health Care 2013;29:48-52.
24. Heller S, McCance DR, Moghissi E, Nazeri A, Kordonouri O. Diversity in diabetes: the role of insulin aspart. Diabetes Metab Res Rev 2012;28:50-61.
25. Senstius J, Harboe E, Westermann H. In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed® 508 insulin pump. Diabetes Technol Ther 2007;9:75-9.